ADMA - Adma stock rises 10% after Q2 revenue nearly doubles net loss narrows

Adma Biologics ( NASDAQ: ADMA ) stock rose ~10% after Q2 revenue grew ~90% year over year.

Total revenues were $33.9M, compared to $17.83M in Q2 2021. The company said the increase was due to a favorable product mix, as it continues to expand its customer base for immune globulin products Bivigam and Asceniv.

"We are particularly pleased with the utilization and growth of our higher margin immune globulin product, ASCENIV™. Drawing from the robust underlying product demand trends, we expect that the product and margin mix will continue to favorably evolve over the coming periods," said President and CEO Adam Grossman.

Q2 Gross Profit was to $7.77M, compared to gross loss -$1M in Q2 2021.

Net loss narrowed to -$13.76M, compared to -$18.91M.

Outlook 2022 :

"We believe we are well-positioned to deliver 2022 total revenues exceeding $130 million, driven by both Intravenous Immunoglobulin (“IVIG”) end-market growth as well as anticipated share gains for our product portfolio," said Grossman.

Consensus Revenue Estimate for 2022 is $132.69M.

The company reiterated expectations for continued gross profit expansion and narrowing net losses as 2022 progresses.

Outlook 2024-2025 :

Adma noted that it continues to expect ~$250M or more in topline revenue in 2024, and ~$300M or more thereafter.

For further details see: